EUCTR2017-003234-82-FR进行中（未招募）1 期
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia type 2 - NTMT-03-A
eurotech Pharmaceuticals0 个研究点目标入组 112 人开始时间: 2018年10月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To participate in this study, the potential participant and at least one of his or her eyes must meet all of the following criteria:
- •1. Participant must have at least one study eye with a positive diagnosis of MacTel Type 2 with evidence of fluorescein leakage typical of MacTel or at least one of the other features including retinal opacification, crystalline deposits, right angle vessels, inner/outer lamellar cavities or hyperpigmentation not involving the center of the fovea, but no evidence of intraretinal/subretinal neovascularization and no evidence of retinal pigment epithelial hyperpigmentation.
- •2. Participant must have an IS/OS PR break and en face ellipsoid zone (area of IS/OS loss) as measured by SD-OCT between 0.16 mm2 and 2.00 mm2.
- •3. Participant's best corrected visual acuity is 54 letter score or better (20/80 or better) as measured by the ETDRS chart;
- •4. Participant must have steady fixation in the foveal or parafoveal area and sufficiently clear media for good quality photographs;
- •5. Participant must be greater than 21 years of age or less than 80 years of age
- •6. Participant must be able to provide a written informed consent to participate in the study, in accordance with the ICH GCP guidelines, and local regulations, before initiating any study related procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 112
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 112
排除标准
- •To participate in this study, the potential participant must not meet any of the following criteria. The ocular exclusion criteria are related to the study eye (unless indicated for either eye):
- •1. Participant is medically unable to comply with study procedures or follow-up visits;
- •2. Participant received intravitreal steroid therapy for non-neovascular MacTel within the last 3 months;
- •3. Participant has ever received intravitreal anti-VEGF therapy for neovascular disease complicating MacTel in either eye;
- •4. Participant has evidence of ocular disease other than MacTel that, in the judgment of the examining physician, may confound the diagnosis, procedures or outcome of the study (e.g., glaucoma, severe non-proliferative or proliferative diabetic retinopathy, uveitis, etc.);
- •5. Participant has a chronic requirement (e.g., = 4 weeks at a time) for ocular medications and/or has a diagnosed disease that, in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted);
- •6. Participant has evidence of intra-retinal/sub-retinal neovascularization in either eye;
- •7. Participant has evidence of central serous chorio-retinopathy (CSCR) in either eye;
- •8. Participant has evidence of pathologic myopia in either eye;
- •9. Participant has significant corneal or media opacities in either eye;
- •10. Participant has had a vitrectomy, penetrating keratoplasty, trabeculectomy or trabeculoplasty
- •11. Participant has any of the following lens opacities: cortical opacity > standard 3, posterior subcapsular opacity > standard 2, or a nuclear opacity > standard 3 as measured on the AREDS clinical lens grading system;
- •12. Participant has undergone lens removal in the previous 3 months or YAG laser within 4 weeks;
- •13. Participant was a study participant in any other clinical trial of an intervention (drug or device ) within the last 6 months;
- •14. Participant is on chemotherapy;
- •15.Participant is pregnant or breastfeeding;
- •16.Participant has a history of malignancy that would compromise the 24-month study survival;
- •17.Participant is on immunosuppressive therapy;
- •18.Participant is considered immunodeficient or has a diagnosis of HIV;
- •19.Participant with a history of ocular Herpes virus in either eye; or
- •20.Participant has, in the opinion of the Investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments.
研究者
相似试验
进行中（未招募）
1 期
A phase III clinical trial to determine the safety and effectiveness of Renexus, an implant in the eye shown to reduce the rate of progression of Macular Telangiectasia type 2Macular Telangiectasia type 2EUCTR2017-003234-82-GBeurotech Pharmaceuticals112
进行中（未招募）
1 期
A phase III clinical trial to determine the safety and effectiveness ofNT-501, an implant in the eye shown to reduce the rate of progression of Macular Telangiectasia type 2Macular Telangiectasia type 2EUCTR2017-003260-12-DEeurotech Pharmaceuticals Inc.112
Unknown
3 期
To study the the Efficacy and Safety of Intravitreal Injection of DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the EyeCTRI/2020/04/024680Santen Incorporated47
进行中（未招募）
1 期
CLINICAL STUDY FINALIZED TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD TREATMENT WITH THE LENALIDOMIDE E DEXAMETHASONE DRUGS COMPARED WITH THE DOSE REDUCTIONS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA THAT CAN NOT RECEIVE THE STANDARD CHEMIOTHERAPYELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTSMedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004166-33-ITFO.NE.SA.Onlus200
进行中（未招募）
不适用
An international study to assess the safety and efficacy of new investigational drugs and standard of care in patients with chronic hepatatis C virus infectioChronic Genotype 2 or 3 HCV InfectionMedDRA version: 14.1Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 10022891 - InvestigationsEUCTR2011-005055-14-NLGilead Sciences Inc.500